Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349251 | 0.87 | EGFR (0.77) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL1192454 | 0.86 | EGFR (1.00) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL3244621 | 0.86 | EGFR (1.00) | EGFRABCG2ALK | |
| SCHEMBL8871504 | 0.86 | EGFR (0.76) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL8871973 | 0.86 | EGFR (0.83) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL30552991 | 0.86 | EGFR (1.00) | EGFRABCG2ALK | |
| SCHEMBL1507459 | 0.83 | EGFR (0.71) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL8871526 | 0.83 | EGFR (0.71) | EGFRABCG2ALKHTT | |
| SCHEMBL17124151 | 0.82 | EGFR (0.84) | EGFRABCG2ALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL1507485 | 0.82 | EGFR (0.69) | EGFRABCG2ALKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | disclosed |
| EP-1673110-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-06-28 | — | — | EP | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005023315-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | disclosed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ABCG2 710/4885ALK 34/4885 |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | EGFR 1/4885ABCG2 483/4885ALK 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.